Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

BRAFV600-mutated colorectal cancer (CRC) accounts for 8% to 12% of all CRC diagnoses. These tumors are often associated with specific patient features, including right-sided primary tumor location, peritoneal and non-regional lymph node involvement, and poor prognosis. In approximately 30% of cases,...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, D'Angelo, Alberto, Petrioli, Roberto, Roviello, Franco, Cianchi, Fabio, Nobili, Stefania, Mini, Enrico, Lavacchi, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Review article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260582/
https://www.ncbi.nlm.nih.gov/pubmed/32470910
http://dx.doi.org/10.1016/j.tranon.2020.100795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260582/
https://www.ncbi.nlm.nih.gov/pubmed/32470910
http://dx.doi.org/10.1016/j.tranon.2020.100795

Ejemplares similares